Affordable Access

deepdyve-link
Publisher Website

Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS.

Authors
  • Benatar, Michael1
  • Wuu, Joanne2
  • Andersen, Peter M2
  • Atassi, Nazem2
  • David, William2
  • Cudkowicz, Merit2
  • Schoenfeld, David2
  • 1 From the Department of Neurology (M.B., J.W.), University of Miami, FL; Department of Pharmacology and Clinical Neuroscience (P.M.A.), Umeå University, Sweden; Department of Neurology (N.A., W.D., M.C.), Massachusetts General Hospital (D.S.), Harvard Medical School; and Department of Biostatistics (D.S.), Harvard Chan School of Public Health, Boston, MA. [email protected] , (Sweden)
  • 2 From the Department of Neurology (M.B., J.W.), University of Miami, FL; Department of Pharmacology and Clinical Neuroscience (P.M.A.), Umeå University, Sweden; Department of Neurology (N.A., W.D., M.C.), Massachusetts General Hospital (D.S.), Harvard Medical School; and Department of Biostatistics (D.S.), Harvard Chan School of Public Health, Boston, MA. , (Sweden)
Type
Published Article
Journal
Neurology
Publisher
Ovid Technologies (Wolters Kluwer) - American Academy of Neurology
Publication Date
Feb 13, 2018
Volume
90
Issue
7
Identifiers
DOI: 10.1212/WNL.0000000000004960
PMID: 29367439
Source
Medline
License
Unknown

Abstract

This study provides Class II evidence that arimoclomol is safe and well-tolerated at a dosage of 200 mg tid for up to 12 months. The study lacked the precision to conclude, or to exclude, an important therapeutic benefit of arimoclomol.

Report this publication

Statistics

Seen <100 times